NEWS RELEASE CONTACTS Investor Contact Jason Starr Gen Gen Media Contact Audra Proctor IR@GenDigital.com Press@GenDigital.com Gen Extends Market Leadership with Record Results in Q2 FY26 Company Raises Outlook as Secure Financial Wellness Fuels Next Stage of Growth TEMPE, Ariz. & PRAGUE – November 6, 2025 – Gen Digital Inc. (NASDAQ: GEN), a global leader dedicated to powering Digital Freedom, released its results for its second quarter fiscal year 2026, which ended October 3, 2025. "Our record results demon ...

Financial Performance - Processa Pharmaceuticals reported a net loss of $3,436,573 for the three months ended September 30, 2025, compared to a net loss of $3,384,703 for the same period in 2024, reflecting an increase of $51,870[78]. - Operating loss for the nine months ended September 30, 2025, was $10,286,616, compared to $9,316,475 for the same period in 2024[78]. - The company generated a net loss of $10.2 million during the nine months ended September 30, 2025, with an accumulated deficit of $97.4 million[98]. - Other income for the three months ended September 30, 2025 was approximately $52,000, compared to $40,000 for the same period in 2024, and for the nine months ended September 30, 2025, it was approximately $74,000 versus $195,000 in 2024[88]. - Net cash used in operating activities for the nine months ended September 30, 2025 was $8,484,617, a decrease from $8,997,321 in 2024, attributed to timing of prepaid asset payments[92]. - The company has incurred losses since inception and does not expect positive cash flow from operations in the foreseeable future[98]. Research and Development - Research and development expenses for the three months ended September 30, 2025, were $1,661,646, a decrease of $625,879 from $2,287,525 in the same period in 2024[78]. - The NGC-Cap Phase 2 trial for advanced or metastatic breast cancer is actively enrolling patients, with preliminary safety-efficacy data expected to inform protocol modifications[69]. - PCS12852, a drug for gastroparesis, is Phase 2B ready, with a binding term sheet signed with Intact Therapeutics for potential licensing, including a $2.5 million payment upon execution[73]. - The company is evaluating the clinical safety and efficacy of PCS499 for primary glomerular diseases, with plans to meet with the FDA in Q4 2025 to discuss the Phase 3 study design[70]. - The company has a pipeline of Next Generation Cancer therapies, with NGC-Cap currently in Phase 2 and NGC-Iri in preclinical development[65]. Expenses and Cash Management - General and administrative expenses for the three months ended September 30, 2025 increased by approximately $681,000 to $1.8 million from $1.1 million for the same period in 2024, primarily due to salary increases and professional fees[86]. - For the nine months ended September 30, 2025, general and administrative expenses rose by approximately $831,000 to $4.6 million from $3.8 million in 2024, driven by salary increases and stock-based compensation[87]. - As of September 30, 2025, the company had cash and cash equivalents totaling $6.3 million, which, along with subsequent proceeds of $945,000, is expected to satisfy capital needs into the first quarter of 2026[97]. Capital Raising and Financing - The company raised net proceeds of $10.6 million through public offerings during the nine months ended September 30, 2025, selling 15,340,972 shares of common stock[71]. - During the nine months ended September 30, 2025, the company raised net proceeds of $12.9 million from selling shares and warrants in various offerings[95]. - The company plans to raise additional funds through equity offerings, debt financings, and strategic alliances, but may face challenges if adequate financing is not obtained[100]. - As of September 30, 2025, the company did not have any off-balance sheet arrangements[103]. Strategic Initiatives - Processa Pharmaceuticals is exploring options for its non-oncology drugs, which may include out-licensing or partnership opportunities[66]. - As of November 3, 2025, Processa Pharmaceuticals owned $850,000 in Digital Assets and plans to engage in capital raising transactions to purchase more Digital Assets[68].

Financial Performance - Net income attributable to common stockholders was $20.1 million, or $0.10 per diluted share, a decrease of 16.3% compared to Q3 2024[5] - Total revenues for Q3 2025 were $285.4 million, an increase of 1.5% compared to Q3 2024[9] - Net income for the three months ended September 30, 2025, was $22,638,000, compared to $26,557,000 for the same period in 2024, reflecting a decrease of approximately 14.4%[43] - Total revenues for the three months ended September 30, 2025, were $285.384 million, slightly up from $285.129 million in the same period of 2024[27] - Total revenues for the year to date 2025 is $842.88 million, with an adjusted EBITDA of $239.86 million[60] - The total revenues for the year to date 2025 show a significant increase compared to the previous year, indicating positive market trends[60] Adjusted EBITDA - Adjusted EBITDA for Q3 2025 was $79.1 million, an increase of 2.7% compared to Q3 2024[5] - Adjusted EBITDA for the nine months ended September 30, 2025, was $225,651,000, slightly down from $228,229,000 in 2024, indicating a decrease of about 1.1%[43] - Hotel Adjusted EBITDA for the three months ended September 30, 2025, was $83,168,000, compared to $82,259,000 in 2024, showing an increase of approximately 1.1%[43] - Total adjusted EBITDA for the comparable total in 2025 is $240.19 million, reflecting a strong performance across the portfolio[60] Shareholder Returns - The company declared a quarterly cash dividend of $0.08 per share, paid on October 14, 2025[14] - The company repurchased 4.8 million shares of common stock year-to-date at an average price of $7.72 per share, totaling approximately $37.1 million[5] Debt and Financial Flexibility - The company successfully refinanced its senior unsecured credit facility to $1.5 billion, enhancing its balance sheet flexibility[10] - The company has no secured debt remaining after repaying mortgage loans for Hotel Clio and Westin Boston Seaport District[11] - The company reported a total debt of $1,100,000 as of September 30, 2025, with a net debt to EBITDA ratio of 3.3x[52] - The weighted-average interest rate on total debt was 5.3% as of September 30, 2025[52] Guidance and Projections - Full year 2025 guidance for Adjusted EBITDA is set at $287 million to $295 million, with an increase of $6.0 million at the midpoint compared to previous guidance[17] - Full year 2025 guidance for net income is projected between $88,433,000 and $97,433,000[44] - The company expects to invest $85.0 to $90.0 million in capital improvements in 2025, a reduction of $5.0 million from prior expectations[10] Operational Metrics - Comparable RevPAR was $214.21, a decrease of 0.3% compared to Q3 2024, while Comparable Total RevPAR increased by 1.5% to $323.29[5] - Comparable total occupancy rate for Q3 2025 was 76.2%, unchanged from Q3 2024[53] - Total RevPAR for comparable hotels decreased by 0.4% to $281.05 in Q3 2025 compared to Q3 2024[53] - The total number of comparable rooms across the portfolio was 9,595[53] Asset and Equity Position - Total assets as of September 30, 2025, were $3.146 billion, a decrease from $3.172 billion as of December 31, 2024[25] - The company’s total stockholders' equity decreased to $1.568 billion as of September 30, 2025, from $1.590 billion as of December 31, 2024[25] - The company’s cash and cash equivalents increased to $145.336 million as of September 30, 2025, up from $81.381 million as of December 31, 2024[25] Hotel Performance - The Chicago Marriott Downtown reported a RevPAR increase of 5.8% to $330.22 in Q3 2025[53] - The Atlanta Marriott in Alpharetta saw a RevPAR increase of 10.0% to $153.08, with occupancy rising to 68.3%[53] - The Bourbon Orleans Hotel experienced a significant RevPAR decline of 14.0% to $177.09, with occupancy dropping to 61.4%[53] - The Embassy Suites by Hilton Bethesda reported a RevPAR decrease of 8.9% to $132.20, with occupancy at 69.6%[53] - The Salt Lake City Marriott Downtown at City Creek achieved a RevPAR increase of 17.8% to $197.87, with occupancy at 70.7%[53]

affirm) First Fiscal Quarter 2026 Shareholder Letter a) ·1234 (0) Pay over time Pay in full <> Purchasing power > Plan a purchase Get your vintage deep cuts for as a low as 0% APR. Shop now → Fellow Affirm Shareholders, We delivered another set of stellar results to get fiscal 2026 started, in both growth and profitability rubrics. Gross Merchandise Volume Revenue Less Transaction ("GMV") Revenue Costs ("RLTC")1 +42% +34% +60% Operating Income Adjusted Operating Income1 Net Income As a percent of Revenue As ...

Third Quarter Key Metrics and Recent Business Highlights EXHIBIT 99.1 BlackLine Announces Third Quarter Financial Results LOS ANGELES, Nov. 06, 2025 (GLOBE NEWSWIRE) -- BlackLine, Inc. (Nasdaq: BL), today announced financial results for the third quarter ended September 30, 2025. "BlackLine's third-quarter results, with increasing revenue growth, solid margins, and strong free cash flow, demonstrate that our focus on improved execution is taking hold," said Owen Ryan, CEO of BlackLine. "The deliberate chang ...

Acquisitions and Strategic Focus - Viatris acquired Aculys Pharma for $35.0 million, gaining rights to develop pitolisant and Spydia® in Japan, expanding its innovative product portfolio [233] - The acquisition of Idorsia Products included an upfront payment of $350 million and potential milestone payments totaling up to $2.4 billion [243] - Viatris' strategic focus includes expanding its portfolio through acquisitions and innovative product development [220] - The company is continuously evaluating potential acquisitions and divestitures as part of its future growth strategy, which may impact future liquidity [328] Financial Performance - Total revenues for the three months ended September 30, 2025, were $3.76 billion, an increase of $8.7 million compared to $3.75 billion in the prior year period [249] - Net sales for the same period were $3.75 billion, reflecting an increase of $9.5 million, or essentially flat, compared to the prior year [253] - The company reported a net loss of $128.2 million for the three months ended September 30, 2025, compared to net earnings of $94.8 million in the prior year, representing a decrease of $223 million [249] - For the nine months ended September 30, 2025, total revenues were $10.60 billion, a decrease of $614.9 million compared to $11.21 billion in the prior year [249] - Net sales for the nine months ended September 30, 2025 were $10.56 billion, down $617.7 million or 6% compared to the previous year [278] - The company recorded a net loss of $3,174.8 million for the nine months ended September 30, 2025, compared to a net loss of $117.7 million for the same period in 2024 [312] Gross Profit and Margins - The gross profit for the three months ended September 30, 2025, was $1.37 billion, down $87.7 million from $1.46 billion in the prior year [249] - Gross profit for the nine months ended September 30, 2025 was $3.87 billion, with gross margins at 36%, down from $4.41 billion and 39% in the prior year [289] - Adjusted gross profit for the three months ended September 30, 2025 was $2.10 billion, with adjusted gross margins at 56%, compared to $2.19 billion and 58% in the prior year [264] - Adjusted gross profit for the same period was $5,952.4 million, resulting in an adjusted gross margin of 56%, down from 58% in 2024 [290] Expenses - R&D expenses increased by $52.0 million to $250.4 million for the three months ended September 30, 2025, primarily due to higher costs for development programs [265] - SG&A expenses decreased by $116.8 million to $886.6 million for the current quarter, mainly due to lower acquisition-related costs [266] - Selling, General and Administrative (SG&A) expenses decreased to $2.76 billion in 2025 from $3.06 billion in 2024, a reduction of $294.5 million attributed to divestitures and lower acquisition-related costs [293] - Interest expense decreased to $351.7 million in 2025 from $429.8 million in 2024, a reduction of $78.1 million due to debt repayments [297] Goodwill and Impairment - The company recorded a non-cash goodwill impairment charge of $2.9 billion due to increased business risks and uncertainties as of March 31, 2025 [236] - The company recorded a goodwill impairment charge of $2.94 billion for the nine months ended September 30, 2025, due to an interim goodwill impairment test [312] - The company performed goodwill impairment tests resulting in total impairment charges of $2,936.8 million across various reporting units as of March 31, 2025 [347] Market and Regulatory Environment - The FDA issued a warning letter and import alert for the Indore manufacturing facility, affecting 11 products distributed in the U.S. [237] - The company faces ongoing risks related to regulatory approvals and market acceptance of new products [227] - Viatris' Developed Markets segment includes operations primarily in North America and Europe, while the Emerging Markets segment covers over 125 countries [224] Cash Flow and Liquidity - Net cash provided by operating activities decreased by $320.1 million to $1.50 billion for the nine months ended September 30, 2025, compared to $1.82 billion in 2024 [315] - Net cash used in investing activities was $216.5 million for the nine months ended September 30, 2025, a decrease of $2.19 billion from net cash from investing activities of $1.97 billion in 2024 [318] - Cash and cash equivalents totaled $975.3 million at September 30, 2025, with significant investments in U.S. government money market funds and bank deposits [322] - The company has access to $3.5 billion under the 2024 Revolving Facility, which matures in September 2029, with no borrowings outstanding as of September 30, 2025 [323] Sales Performance by Region - Net sales in Developed Markets decreased by $43.1 million, or 2%, primarily due to the Indore Impact of approximately $100 million [258] - Net sales from Greater China increased by $53.4 million, or 10%, driven by strong growth across multiple channels [259] - Emerging Markets saw an increase in net sales of $37.2 million, or 7%, primarily due to higher volumes and pricing of existing products [261] - Net sales from Greater China increased by $114.9 million, or 7%, for the nine months ended September 30, 2025, driven by strong growth across multiple channels [283] Future Projections and Estimates - The North America reporting unit had a revenue compound annual growth rate forecast of approximately 3.1% over the next 10 years [347] - The Europe reporting unit had a revenue compound annual growth rate forecast of approximately 3.3% over the next 10 years [348] - The Emerging Markets reporting unit had a revenue compound annual growth rate forecast of approximately 3.5% over the next 10 years [349] - The revenue compound annual growth rate forecasted for the next 10 years is approximately 1.6% [352]

Revenue Performance - Third quarter SaaS revenue reached $84.0 million, reflecting a 38% year-over-year growth, and 35% on a constant currency basis[1] - Total revenue for the third quarter was $109.7 million, representing a 24% year-over-year growth, and 21% on a constant currency basis[1] - Total Annual Recurring Revenue (ARR) as of September 30, 2025, was $390.0 million, indicating a 26% year-over-year growth[1] - Total revenue for the three months ended September 30, 2025, was $109.728 million, a 23.5% increase from $88.804 million in the same period of 2024[17] - SaaS revenue reached $83.982 million, up 37.9% from $60.866 million year-over-year[17] Profitability Metrics - GAAP gross profit for the third quarter was $81.6 million, with a gross margin of 74.4%, compared to 76.1% in the same quarter of 2024[5] - Non-GAAP operating income for the third quarter was $24.1 million, up from $17.8 million in the third quarter of 2024, with a non-GAAP operating margin of 22.0%[5] - The company reported a gross profit of $81.583 million for the three months ended September 30, 2025, compared to $67.583 million in the same period of 2024, representing a 20.7% increase[17] - GAAP operating income for Q3 2025 was $8,129 million, up from $7,652 million in Q3 2024, representing a growth of 6.2%[22] - Non-GAAP operating income for the nine months ended September 30, 2025, reached $56,298 million, compared to $33,184 million for the same period in 2024, an increase of 69.5%[22] - GAAP gross profit for Q3 2025 was $81,583 million, compared to $67,583 million in Q3 2024, reflecting a year-over-year increase of 20.7%[22] - Non-GAAP gross profit for the nine months ended September 30, 2025, was $228,529 million, up from $182,932 million in 2024, indicating a growth of 24.9%[22] Expenses Overview - Operating expenses increased to $73.454 million for the three months ended September 30, 2025, from $59.931 million in the same period of 2024, reflecting a 22.5% rise[17] - The company reported a significant increase in sales and marketing expenses, which rose to $35.593 million for the three months ended September 30, 2025, compared to $30.050 million in the same period of 2024[17] - GAAP sales and marketing expenses for Q3 2025 were $35,593 million, an increase from $30,050 million in Q3 2024, representing a rise of 18.4%[22] - GAAP general and administrative expenses for Q3 2025 were $23,925 million, compared to $17,043 million in Q3 2024, showing a growth of 40.4%[22] - Non-GAAP research and development expenses for Q3 2025 were $11,861 million, up from $10,668 million in Q3 2024, reflecting an increase of 11.1%[22] Retention Rates - The dollar-based gross retention rate was 88%, while the dollar-based net retention rate was 110%[5] Strategic Initiatives - The company announced new data protection solutions for platforms including Monday.com, Docusign, and Google Virtual Machines[5] - AvePoint launched an enhanced points-based Global Partner Program aimed at accelerating growth through partner engagement[5] - The company raised its full-year guidance for revenue and non-GAAP operating income based on third quarter outperformance[5] - AvePoint is now dual-listed on Nasdaq and the Singapore Exchange, becoming the first B2B SaaS stock on the SGX-ST[5] Cash and Assets - Cash and cash equivalents at the end of the period were $471.640 million, up from $290.735 million at the end of December 31, 2024[19] - Total assets increased to $743.515 million as of September 30, 2025, from $519.055 million as of December 31, 2024[19] Share Metrics - The weighted average shares outstanding for diluted earnings per share was 232,897 thousand for the three months ended September 30, 2025, compared to 203,859 thousand in the same period of 2024[17] Cash Flow - Net cash provided by operating activities was $55.598 million for the nine months ended September 30, 2025, slightly down from $56.134 million in the same period of 2024[20] Operating Margins - Non-GAAP operating margin improved to 22.0% in Q3 2025 from 20.1% in Q3 2024[22] - Non-GAAP sales and marketing expenses as a percentage of revenue decreased to 29.9% in Q3 2025 from 31.2% in Q3 2024[22] - Non-GAAP general and administrative expenses as a percentage of revenue decreased to 12.4% in Q3 2025 from 13.6% in Q3 2024[22]

Investment Income - Total investment income for Q3 2025 was $37.3 million, a decrease of 2.9% compared to $38.4 million in Q3 2024[4] - Net investment income decreased by 18.9% to $17.4 million, or $0.49 per share, down from $21.4 million, or $0.64 per share in the same period last year[8] - Adjusted net investment income was $17.7 million, or $0.50 per share, compared to $20.4 million, or $0.61 per share in Q3 2024, reflecting a 13.2% decline[6] - Net investment income for the three months ended September 30, 2025, was $17,369,000, compared to $21,411,000 for the same period in 2024, reflecting a decrease of approximately 18.5%[32] - Adjusted net investment income for the three months ended September 30, 2025, was $17,723,000, down from $20,424,000 in 2024, reflecting a decline of 13.3%[36] - For the nine months ended September 30, 2025, net investment income totaled $54,219,000, slightly down from $55,988,000 in 2024, a decrease of 3.2%[36] - Adjusted net investment income for the nine months ended September 30, 2025, was $56,191,000, compared to $56,930,000 in 2024, a decline of 1.3%[36] Investment Activity - The company invested $74.5 million in debt and equity securities during the quarter, including one new portfolio company[4] - Subsequent to the quarter end, the company invested $40.2 million in two new portfolio companies, indicating a strong pipeline for future investments[3] Asset and Portfolio Valuation - As of September 30, 2025, the net asset value (NAV) was $711.0 million, or $19.56 per share[4] - The fair value of the investment portfolio totaled $1.2 billion, consisting of 92 active portfolio companies[10] - Total assets increased to $1,277,748,000 as of September 30, 2025, compared to $1,164,112,000 on December 31, 2024, representing a growth of approximately 9.7%[30] - Total investments at fair value rose to $1,192,748,000, up from $1,090,506,000, indicating an increase of about 9.4%[30] - Net asset value per common share increased to $19.56 as of September 30, 2025, from $19.33 at the end of 2024, a rise of approximately 1.2%[30] Expenses and Liabilities - Total expenses for Q3 2025 were $19.9 million, an increase of 17.2% from $17.0 million in Q3 2024[7] - Interest and financing expenses increased to $7,649,000 for the three months ended September 30, 2025, compared to $6,026,000 in 2024, an increase of approximately 26.9%[32] - The total liabilities increased to $566,714,000 as of September 30, 2025, from $508,446,000 at the end of 2024, representing a rise of approximately 11.5%[30] Dividends - The company declared total dividends of $0.50 per share for Q4 2025, consisting of a base dividend of $0.43 and a supplemental dividend of $0.07[13] - The company declared dividends of $0.57 per share for the three months ended September 30, 2025, consistent with the same period in 2024[32] Realized Losses - The company reported a net realized loss on investments of $930,000 for the three months ended September 30, 2025, compared to a loss of $366,000 in 2024[32] - The capital gains incentive fee expense for the three months ended September 30, 2025, was a reversal of $354,000, compared to an expense of $(987,000) in 2024[36] - The capital gains incentive fee expense for the nine months ended September 30, 2025, was $1,972,000, up from $942,000 in 2024[36]

Revenue and Profitability - Revenue for Q3 2025 was $50.2 million, an 11% increase from $45.1 million in Q3 2024[5] - Gross profit for Q3 2025 was $39.7 million, with a gross margin of 79.1%, compared to 80.1% in Q3 2024[5] - Net loss for Q3 2025 was $(16.3) million, or $(0.26) per share, compared to $(15.4) million, or $(0.25) per share in Q3 2024[6] - Adjusted EBITDA loss improved by 49% to $(2.6) million in Q3 2025, compared to $(5.1) million in Q3 2024[6] - Net loss for the nine months ended September 30, 2025, was $49,608 million, an improvement from a net loss of $55,242 million for the same period in 2024, reflecting a reduction of approximately 10.4%[25] - Adjusted EBITDA for the nine months ended September 30, 2025, was $(10,080) million, compared to $(22,064) million for the same period in 2024, indicating a significant improvement[27] Expenses and Liabilities - Total operating expenses increased by 8% to $55.4 million in Q3 2025, up from $51.3 million in Q3 2024[6] - Current liabilities increased from $34,925 million to $40,908 million, an increase of about 17.5%[23] - Share-based compensation expense increased from $22,048 million in the nine months ended September 30, 2024, to $26,268 million in the same period of 2025, an increase of about 19%[27] - The company reported a net cash used in operating activities of $(7,944) million for the nine months ended September 30, 2025, compared to $(32,960) million for the same period in 2024, showing a significant improvement in cash flow[25] Guidance and Projections - The company revised its full-year 2025 revenue guidance to $211 million to $213 million, reflecting a growth of 1% to 2% compared to 2024[9] - Expected Adjusted EBITDA loss for full-year 2025 is now projected to be between $(6.5) million and $(7.5) million, a 32% to 41% improvement over the prior year[9] Assets and Equity - Total assets decreased from $217,094 million as of December 31, 2024, to $196,591 million as of September 30, 2025, representing a decline of approximately 9.4%[23] - Total stockholders' equity decreased from $112,892 million as of December 31, 2024, to $89,187 million as of September 30, 2025, a decline of approximately 21.1%[23] Liquidity - Total liquidity as of September 30, 2025, was $80.6 million, consisting of $57.4 million in cash and $23.2 million available under the revolving loan facility[8] Technology and Patents - The company expanded its bunion technology portfolio with the market release of new systems, including Nanoplasty® and Percuplasty™[7] - The global patent portfolio now totals 122 granted patents and 194 pending applications[7] Litigation - The company incurred litigation costs of $2,548 million related to patent infringement lawsuits during the nine months ended September 30, 2025[28] Debt - The company’s long-term debt remained relatively stable, increasing slightly from $53,306 million to $53,529 million[23]

Financial Performance - Net Revenue for Q3 2025 increased by 4% year over year to a record $376 million[1] - Net Income for Q3 2025 increased by 2% year over year to $39 million, reflecting a 10% margin[1] - Adjusted EBITDA for Q3 2025 decreased by 3% year over year to $98 million, reflecting a 26% margin[1] - Net income for the three months ended September 30, 2025, was $38,440,000, with a net income margin of 10%[20] - Adjusted EBITDA for the same period was $101,364,000, resulting in an Adjusted EBITDA margin of 26%[20] - Total net revenue for the three months ended September 30, 2025, was $360,344,000, compared to $376,038,000 for the same period in 2024[20] - The company reported strong profitability despite ongoing macro challenges, with Services driving business performance[2] Financial Outlook - The company updated its 2025 Net Revenue outlook to a range of $1.460 billion to $1.465 billion[1] - The 2025 Adjusted EBITDA outlook was updated to a range of $360 million to $365 million[1] Cash Flow and Assets - Net cash provided by operating activities for the nine months ended September 30, 2025, was $287.547 million, compared to $214.842 million for the same period in 2024[15] - Free cash flow for the three months ended September 30, 2025, was $118,937,000, compared to $92,535,000 for the same period in 2024, reflecting a year-over-year increase of 28.7%[20] - Net cash provided by operating activities for the three months ended September 30, 2025, was $131,518,000, up from $102,298,000 in the prior year[20] - Total current assets as of September 30, 2025, were $550.298 million, up from $516.879 million at the end of 2024[11] - Total liabilities as of September 30, 2025, were $256.731 million, compared to $239.598 million at the end of 2024[11] - Net cash used in financing activities for the nine months ended September 30, 2025, was $237,779,000[20] Expenses - The company recorded depreciation and amortization expenses of $9,326,000 for the three months ended September 30, 2025[20] - Stock-based compensation expense for the three months ended September 30, 2025, was $39,472,000[20] - The company expects to be indemnified for certain expenses related to the RepairPal acquisition, which will be excluded from Adjusted EBITDA calculations[20] Product Development - The rollout of over 35 new features and updates, including AI-powered services, is part of the company's product-led strategy[2]